TY - JOUR
T1 - Thrombotic and embolic complications with silastic ball prosthetic valves
AU - Macmanus, Q.
AU - Metzdorff, M. T.
AU - Grunkemeier, G. L.
AU - Starr, A.
PY - 1984
Y1 - 1984
N2 - Eighteen years of continous clinical use with the Starr-Edwards ball-valve prosthesis provides an extensive data base for comparison with more recently introduced cardiac prostheses, and establishes the credentials of this valve for current clinical use. Since 1965, 558 aortic (model 1260) and 285 mitral (model 6120) ball-valve prostheses have been inserted at the University of Oregon. Thromboembolic rates for the entire series (1965-1983) and our more recent experience (1973-1983) were 3.8% per year and 2.8% per year for the aortic valve; and 5.1% per year and 2.6% per year for the mitral valve. Patients who had experienced one embolic episode were substantially more likely to experience a subsequent event. Thrombotic stenosis was seen at rates of 0.1% per patient year and 0.4% per patient year for the aortic and mitral valves, respectively. These results are compared with other current series using a variety of mechanical and tissue protheses. The Starr-Edwards valve remains a durable mechanical cardiac prosthesis with thromboembolic complications similar to most other current prostheses. Thrombotic stenosis tends to be rare, gradual, and electively managed as opposed to the sudden, unpredictable, and catastrophic thrombosis seen with tilting disc valves.
AB - Eighteen years of continous clinical use with the Starr-Edwards ball-valve prosthesis provides an extensive data base for comparison with more recently introduced cardiac prostheses, and establishes the credentials of this valve for current clinical use. Since 1965, 558 aortic (model 1260) and 285 mitral (model 6120) ball-valve prostheses have been inserted at the University of Oregon. Thromboembolic rates for the entire series (1965-1983) and our more recent experience (1973-1983) were 3.8% per year and 2.8% per year for the aortic valve; and 5.1% per year and 2.6% per year for the mitral valve. Patients who had experienced one embolic episode were substantially more likely to experience a subsequent event. Thrombotic stenosis was seen at rates of 0.1% per patient year and 0.4% per patient year for the aortic and mitral valves, respectively. These results are compared with other current series using a variety of mechanical and tissue protheses. The Starr-Edwards valve remains a durable mechanical cardiac prosthesis with thromboembolic complications similar to most other current prostheses. Thrombotic stenosis tends to be rare, gradual, and electively managed as opposed to the sudden, unpredictable, and catastrophic thrombosis seen with tilting disc valves.
UR - http://www.scopus.com/inward/record.url?scp=0021717366&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021717366&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/5.suppl_d.59
DO - 10.1093/eurheartj/5.suppl_d.59
M3 - Article
C2 - 6519104
AN - SCOPUS:0021717366
SN - 0195-668X
VL - 5
SP - 59
EP - 63
JO - European Heart Journal
JF - European Heart Journal
IS - SUPPL. D
ER -